OBBeC.com

Mountain View, CA and London, UK (OBBeC) - Pharsight, a provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, and InforSense, a provider of next-generation business and scientific intelligence tools, today announced that they have signed an agreement for InforSense to distribute Pharsight products in China through its Shanghai based subsidiary.

As part of the agreement, InforSense will represent Pharsight’s software for pharmacokinetic and pharmacodynamic (PK/PD) analysis, reporting, archiving, and data visualization. InforSense will provide distribution services for Pharsight within the Chinese pharmaceutical and biotech research and development market, including sales and marketing, end-user training, and maintenance and support services.
Pharsight and InforSense have also initiated a strategic partnership to deliver translational research solutions to the pharmaceutical industry. The strategic partnership includes opportunities for product-based collaborations to utilize biomarkers in clinical PK/PD modeling.

“This agreement strengthens Pharsight’s ability to take advantage of the exceptional growth opportunities in China as research and development activities expand,” said Dr. Daniel L. Weiner, senior vice president and chief technology officer at Pharsight. “There is a strong demand in our customer base for more dynamic analysis and visualization of PK/PD data and the integration of genotypic and other biomarker data. Partnering with InforSense will enable Pharsight to take advantage of their flexible, high-throughput analytics technology and expertise with molecular data to enable more effective PK/PD modeling. We look forward to a successful distribution alliance and fruitful collaboration, based on the respective strengths of each company’s tools and technologies.”